Decheng Capital LLC lowered its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 15.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 65,000 shares of the company's stock after selling 11,772 shares during the period. Krystal Biotech makes up about 3.3% of Decheng Capital LLC's holdings, making the stock its 6th biggest position. Decheng Capital LLC owned 0.22% of Krystal Biotech worth $11,720,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its stake in Krystal Biotech by 4.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock valued at $762,000 after acquiring an additional 190 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Krystal Biotech in the fourth quarter valued at approximately $674,000. LPL Financial LLC grew its stake in Krystal Biotech by 156.8% in the fourth quarter. LPL Financial LLC now owns 2,946 shares of the company's stock valued at $462,000 after acquiring an additional 1,799 shares during the period. Vanguard Group Inc. grew its stake in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Krystal Biotech by 18.7% during the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock valued at $23,786,000 after buying an additional 23,934 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.
Krystal Biotech Stock Up 2.0%
KRYS traded up $3.11 during midday trading on Friday, reaching $156.98. The company had a trading volume of 571,859 shares, compared to its average volume of 319,534. The business has a 50-day moving average of $140.19 and a two-hundred day moving average of $155.65. The company has a market cap of $4.54 billion, a P/E ratio of 37.74 and a beta of 0.67. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $207.84.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.
Analyst Ratings Changes
Several brokerages recently issued reports on KRYS. Bank of America cut their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Citigroup reissued a "neutral" rating and set a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Friday, July 25th. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Friday, July 25th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $211.33.
Read Our Latest Research Report on Krystal Biotech
Insider Activity
In other news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the transaction, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. The trade was a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by company insiders.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
